ERBB2 and cancer: We have developed a therapeutic cancer vaccine targeting HER2 based on autologous dendritic cells (DCs) transduced with an adenovirus (AdHER2) expressing the non-signaling extracellular and transmembrane domains of HER2, a driver oncogene in many cancers that is often associated with worse outcome.